? PROTOCOL REVIEW AND MONITORING SYSTEM The PRMS at Fox Chase Cancer Center (FCCC) is spearheaded by the Research Review Committee (RRC). The RRC evaluates and provides scientific prioritization of all therapeutic trials at FCCC, with particular emphasis on investigator initiated studies. The RRC is comprised of physicians from all oncologic disciplines, translational researchers, pharmacists, biostatisticians, as well as researchers from nursing and the Cancer Prevention and Control Program. In addition all new protocols that contain human research at FCCC are reviewed. Prior to scientific review, Disease Site Teams, with input from Translational Research Disease Groups, determine the clinical priority of interventional studies, based on their clinical research agenda and the existence of competing trials. Once submitted for review, the Clinical Trials Office (CTO) feasibility committee evaluates protocols to determine if sufficient resources will or will not be available from the CTO. With the affiliation with Temple University Health System, studies arising on the Temple University Health Science Center campus are subject to the same review process. The goals of the review are to ensure that the study being evaluated has: 1. A clear hypothesis 2. A relevant biologic or therapeutic question 3. Appropriate scientific design to answer the question being asked 4. Appropriate resources for the conduct of the study 5. Appropriate statistical design to answer the question being asked 6. Appropriate data and safety oversight, if applicable 7. Scientific prioritization for therapeutic trials supported by CTO resources The RRC is also responsible for monitoring accrual at the time of the annual continuing reviews, to ensure that the use of ongoing CTO resources in support of studies is justified. To assist with this function, the Protocol Accrual Subcommittee (PAC) of the RRC has been formed. The subcommittee meets bi-weekly to review accruals and communicate with investigators whose protocols are at risk for termination due to poor accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006927-51
Application #
9147888
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
51
Fiscal Year
2016
Total Cost
$114,720
Indirect Cost
$50,451
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580

Showing the most recent 10 out of 1280 publications